We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sysmex Enters into R&D and Licensing Agreement with Merck Millipore
News

Sysmex Enters into R&D and Licensing Agreement with Merck Millipore

Sysmex Enters into R&D and Licensing Agreement with Merck Millipore
News

Sysmex Enters into R&D and Licensing Agreement with Merck Millipore

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sysmex Enters into R&D and Licensing Agreement with Merck Millipore"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sysmex Corporation has entered into a clinical research, joint development and licensing agreement with Merck Millipore involving Merck Millipore imaging flow cytometry technology. 

If successful, Sysmex and Merck Millipore will collaborate on developing the imaging flow technology platform for the future commercialization in hematology.  

Sysmex has developed various products to analyze cells within the blood, using flow cytometry (FCM) as a platform that can be easily deployed in a clinical setting.

This agreement involves the imaging flow cytometry technology developed by Amnis which was acquired by Merck Millipore in 2011. It is a unique, highly differentiated technology platform that combines the power of flow cytometry with rapid capture of high volume images of cell morphology, fluorescent imaging, and automated digital image analysis. The clinical study will assess the use of imaging flow cytometry technology as a platform for diagnosing hematologic disorders such as leukemia.

Once clinical research is complete, the parties intend to develop more powerful diagnostic tools that will generate image data of molecular (protein) expression status, as well as the identification of abnormal cells in the blood. Sysmex aims to promote the creation of new diagnostic technologies that will enable the realization of personalized medicine and contribute to the advancement of healthcare by meeting increasingly diverse and sophisticated testing needs.

Advertisement